FMP
Protagenic Therapeutics, Inc.
PTIX
NASDAQ
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
1.37 USD
-0.06 (-4.38%)
About
ceo
Dr. Garo H. Armen Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.protagenic.com
exchange
NASDAQ
Description
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
CIK
0001022899
ISIN
US74365N2027
CUSIP
74365N103
Address
149 Fifth Avenue
Phone
212 994 8200
Country
US
Employee
1
IPO Date
Apr 27, 2021
Key Executives
